REGENXBIO Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.73M | $22.89M | 0.00% | Added+19.4% | 2026-03-31 |
| TwoSigma | quant | 554.9K | $4.65M | 0.00% | Added+327.0% | 2026-03-31 |
| FidelityFMR | fundamental | 311.3K | $2.61M | 0.00% | Added+17.0% | 2026-03-31 |
| RenTech | quant | 305.3K | $2.56M | 0.00% | Trimmed-8.3% | 2026-03-31 |
| DEShaw | quant | 286.0K | $2.40M | 0.00% | Added+318.2% | 2026-03-31 |
| Citadel | multi-strat | 139.8K | $1.17M | 0.00% | Added+318.7% | 2026-03-31 |
| TRowePrice | fundamental | 51.1K | $429 | 0.00% | Added+31.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 0.34 | — | — |
| 2026-05-14 | -1.41 | -1.72 | -21.64% |
| 2026-03-05 | -0.84 | -1.30 | -54.92% |
| 2025-11-06 | -1.30 | -1.20 | +7.57% |
| 2025-08-07 | -1.05 | -1.38 | -30.83% |
| 2025-05-12 | 0.34 | 0.12 | -64.48% |
| 2025-03-13 | -1.08 | -1.01 | +6.86% |
| 2024-11-06 | -1.10 | -1.17 | -6.58% |
| 2024-08-01 | -1.31 | -1.05 | +20.12% |
| 2024-05-08 | -1.26 | -1.34 | -6.24% |
| 2024-02-27 | -1.28 | -1.43 | -11.79% |
| 2023-11-08 | -1.52 | -1.41 | +7.08% |
| 2023-08-02 | -1.21 | -1.66 | -37.69% |
| 2023-05-03 | -1.41 | -1.53 | -8.77% |
| 2023-02-28 | -1.17 | -1.38 | -17.78% |
| 2022-11-03 | -1.46 | -1.75 | -19.60% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RGNX | -23.14% | -23.30% | -51.32% | -32.27% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -26.11% | -18.48% | -47.88% | -44.89% |